-transparent.png){kind=logo}
The functions of human pulmonary alveolar macrophages (PAMs) have been relatively little studied compared with those of their circulating counterparts, blood monocytes. This study examined the ability of human PAMs to kill primary human tumor cell cultures and control normal fibroblasts in vitro. PAMs were derived by bronchial lavage from patients with lung cancer of various histological types and stages, patients with acute or chronic noncancerous pulmonary disorders, and subjects with a presumed illness who proved to be normal. After extensive washing, the PAMs were cocultured with [3H]proline-labeled tumor cells, principally lung cancers and melanomas, at various effector:target ratios for 60 hr. Cytotoxicity was measured by comparing radioactivity associated with the remaining adherent tumor cells cultured in the presence or absence of PAMs. Twenty-eight of 42 preparations of PAMs from 42 individuals were cytotoxic to one or more short-term primary tumor cultures. All 28 specimens from patients with lung cancer or chronic pulmonary disease were cytotoxic; all of the 14 PAM preparations lacking cytotoxicity were from individuals with acute pulmonary disorders or who were proved free of pulmonary disease. PAMs were cytotoxic even at effector:target ratios of 2.5:1 or 1.25:1. Fibroblasts were unaffected at any ratio. Sarcoidosis patients in remission had noncytotoxic PAMs, whereas the disease in relapse was characterized by cytotoxic PAMs. Serial study of 2 patients confirmed a loss of reactivity during remission. Smoking did not correlate with the presence or absence of spontaneous cytotoxicity and did not influence the degree of cytotoxicity in "reactors." Partially purified alpha-interferon enhanced the killing of cytotoxic PAMs in 10 of 21 instances but did not induce cytotoxicity in 9 tests on nonreactive PAMs. We conclude that human PAMs from patients with lung cancer or chronic pulmonary diseases, including active sarcoidosis, were cytotoxic to several recently explanted tumor cell cultures. PAMs from acute pulmonary dysfunctions and those from patients with inactive sarcoidosis were not spontaneously cytotoxic.
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
February 1984,
The American review of respiratory disease,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
November 1990,
Infection and immunity,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
May 1991,
Journal of toxicology and environmental health,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
February 1988,
Medicina clinica,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
January 1990,
Agents and actions. Supplements,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
April 1979,
Cancer letters,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
January 2003,
Problemy tuberkuleza i boleznei legkikh,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
March 1994,
The Clinical investigator,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
May 1983,
Anesthesiology,
J Kan-Mitchell, and
J C Hengst, and
R A Kempf, and
R K Rothbart, and
S M Simons, and
A S Brooker, and
V L Kortes, and
M S Mitchell
November 1991,
Chest,
